articleTop 1% cited

Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

Clinical Cancer Research · 2006 · Vol. 12(14) · pp. 4218–4224

Daniel F. Hayes✉(University of Michigan–Ann Arbor)Massimo Cristofanilli(University of Michigan–Ann Arbor)G. Thomas Budd(University of Michigan–Ann Arbor)Matthew J. Ellis(Washington University in St. Louis)Alison Stopeck(Arizona Oncology)Michael Craig Miller(University of Michigan–Ann Arbor)Jeri Matera(University of Michigan–Ann Arbor)W. Jeffrey Allard(Eon Corporation (United States))Gerald V. Doyle(University of Michigan–Ann Arbor)Leon W.M.M. Terstappen(Eon Corporation (United States))

View via DOI Publisher page

Abstract

Detection of elevated CTCs at any time during therapy is an accurate indication of subsequent rapid disease progression and mortality for MBC patients.

Cancer Cells and Metastasis Cancer Genomics and Diagnostics Advanced Breast Cancer TherapiesMedicineMetastatic breast cancerCirculating tumor cellProgression-free survivalInternal medicineOverall survivalBreast cancerOncologyCancerMetastasis

MeSH terms

Breast NeoplasmsDouble-Blind MethodFollow-Up StudiesHumansNeoplastic Cells, CirculatingNeoplasm MetastasisProspective StudiesTime FactorsProportional Hazards ModelsTreatment OutcomeDisease ProgressionDisease-Free Survival

Citations

1,042

FWCI

15.33

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System